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ABSTRACT
Adenylyl cyclases (ACs) catalyze the conversion of ATP into the
second messenger cAMP and play a key role in signal trans-
duction. In a recent study (Mol Pharmacol 70:878–886, 2006),
we reported that 2,3-O-(2,4,6-trinitrophenyl)-substituted nu-
cleoside 5-triphosphates (TNP-NTPs) are potent inhibitors (Ki
values in the 10 nM range) of the purified catalytic subunits VC1
and IIC2 of membranous AC (mAC). The crystal structure of
VC1:IIC2 in complex with TNP-ATP revealed that the nucleotide
binds to the catalytic site with the TNP-group projecting into a
hydrophobic pocket. The aims of this study were to analyze the
interaction of TNP-nucleotides with VC1:IIC2 by fluorescence
spectroscopy and to analyze inhibition of mAC isoforms, solu-
ble AC (sAC), soluble guanylyl cyclase (sGC), and G-proteins by
TNP-nucleotides. Interaction of VC1:IIC2 with TNP-NDPs and
TNP-NTPs resulted in large fluorescence increases that were
differentially reduced by a water-soluble forskolin analog. TNP-
ATP turned out to be the most potent inhibitor for ACV (Ki, 3.7
nM) and sGC (Ki, 7.3 nM). TNP-UTP was identified as the most
potent inhibitor for ACI (Ki, 7.1 nM) and ACII (Ki, 24 nM).
TNP-NTPs inhibited sAC and GTP hydrolysis by Gs- and Gi-
proteins only with low potencies. Molecular modeling revealed
that TNP-GTP and TNP-ATP interact very similarly, but not
identically, with VC1:IIC2. Collectively, our data show that TNP-
nucleotides are useful fluorescent probes to monitor conforma-
tional changes in VC1:IIC2 and that TNP-NTPs are a promising
starting point to develop isoform-selective AC and sGC inhib-
itors. TNP-ATP is the most potent sGC inhibitor known so far.
ACs catalyze the conversion of ATP into the second mes-
senger cAMP and play a key role in signal transduction. In
mammals, nine membranous AC isoforms (ACI–IX) have
been identified (Defer et al., 2000; Sunahara and Taussig,
2002). mACs differ from each other in regulation and tissue
expression, and studies with transgenic and gene-knock-out
mice have revealed different functions for the various AC
isoforms. Most strikingly, ACV is an important AC isoform in
the heart (Göttle et al., 2009), and the knock-out of ACV
protects mice against heart failure and induces longevity
(Yan et al., 2007). Thus, ACV inhibitors may be valuable
drugs for the treatment of cardiovascular diseases and age-
ing (Iwatsubo et al., 2004; Göttle et al., 2009). In addition to
mACs, mammals express a structurally distinct sAC that is
predominantly found in testis and is important for sperm
maturation (Chen et al., 2000). Thus, sAC inhibitors may be
promising candidates for male contraceptives (Schlicker et
al., 2008). Finally, sGC, catalyzing the conversion of GTP into
This work was supported in part by the Deutsche Forschungsgemeinschaft
[Grants Se529/5-1] (to R.S.); a predoctoral fellowship of the Studienstiftung
des Deutschen Volkes (to A.G.); a predoctoral fellowship from the Elite Grad-
uate Student Program of the Free State of Bavaria (to M.H.); and the National
Institutes of Health [Grant R01-DK46371] (to S.R.S.).
1 Current affiliation: Department of Microbiology and Molecular Genetics,
Medical College of Wisconsin, Milwaukee, Wisconsin.
2 Current affiliation: Research and Development, Cardiovascular Diseases,
Sanofi-Aventis, Frankfurt/Main, Germany.
Article, publication date, and citation information can be found at
http://jpet.aspetjournals.org.
doi:10.1124/jpet.109.155432.
ABBREVIATIONS: AC, adenylyl cyclase; mAC, membranous adenylyl cyclase; sAC, soluble adenylyl cyclase; 2AR, 2-adrenoceptor; Gi,
inhibitory G-protein -subunit; GsS, short splice variant of the stimulatory G-protein -subunit; GsL, long splice variant of the stimulatory
G-protein -subunit; Golf, olfactory G-protein -subunit; sGC, soluble guanylyl cyclase; FPR, formyl peptide receptor; FS, forskolin; GPCR,
G-protein-coupled receptor; DMB-FS, 7-acetyl-7-[O-(N-methylpiperazino)--butyryl]-forskolin; MANT, 2(3)-O-(N-methylanthraniloyl); TNP, 2,3-
O-(2,4,6-trinitrophenyl); VC1 and IIC2, the N- and C-terminal catalytic domains from canine type V mAC and rat type II mAC, respectively,
expressed as soluble proteins; GTPS, guanosine 5-[-thio]triphosphate.
0022-3565/09/3303-687–695$20.00
THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS Vol. 330, No. 3
Copyright © 2009 by The American Society for Pharmacology and Experimental Therapeutics 155432/3501184
JPET 330:687–695, 2009 Printed in U.S.A.
687
the second messenger cGMP, is a nucleotidyl cyclase struc-
turally related to mAC (Sunahara et al., 1998). sGC is acti-
vated by NO, and NO-containing drugs are effective in the
treatment of coronary heart disease and hypertensive crisis
(Koesling et al., 2004; Derbyshire and Marletta, 2009;
Schmidt et al., 2009). sGC inhibitors may be valuable exper-
imental tools to study the role of this enzyme in cardiovas-
cular and neuronal functions (Gille et al., 2004).
mACs are activated by the G-protein Gs and require two
divalent metal cations for catalysis (Sunahara and Taussig,
2002). ACs I–VIII are also activated by FS (Pinto et al., 2008,
2009). mACs consist of two membrane domains with six
transmembrane helices each and two cytosolic domains. The
two cytosolic domains, referred to as C1 and C2, form the
catalytic core of AC, including the ATP-binding site, the
FS-binding site, and the Gs-binding site, whereas the func-
tion of the transmembrane domains is as yet poorly defined
(Sunahara and Taussig, 2002). Several crystal structures of
the cytosolic domains of C1 and C2 (VC1:IIC2) in complex
with Gs, FS, or DMB-FS and various nucleotides have been
resolved, providing detailed insight into the mechanisms of
catalysis and enzyme inhibition (Tesmer et al., 1997, 2000;
Mou et al., 2005, 2006).
MANT-nucleotides (Hiratsuka, 1983; Jameson and Ec-
cleston, 1997) are potent ACV inhibitors and block activation
of voltage-dependent calcium channels in cardiomyocytes,
but so far, the selectivity of mAC inhibitors is not satisfying
(Gille et al., 2004; Rottlaender et al., 2007; Göttle et al.,
2009). The MANT-group inserts like a wedge into a hydro-
phobic pocket between C1 and C2 and prevents transition of
AC from the catalytically inactive closed to the catalytically
active open conformation (Mou et al., 2005, 2006). Hydropho-
bic interactions between the MANT-group and C1:C2 pocket
contribute very substantially to binding affinity, rendering
MANT-nucleotides the most potent mAC inhibitors known so
far (Gille et al., 2004; Mou et al., 2005; Göttle et al., 2009).
Because the MANT-group is fluorescent and sensitive to
changes in hydrophobicity (Hiratsuka, 1983; Jameson and
Eccleston, 1997), the interaction of MANT-nucleotides with
the hydrophobic pocket provided a unique opportunity to
monitor nucleotide binding to and conformational changes of
VC1:IIC2 (Mou et al., 2005, 2006; Pinto et al., 2009).
Because MANT-nucleotides are potent AC inhibitors but
not particularly mAC isoform-specific, we went on to explore
the interaction of other nucleotides with AC. Specifically, in
a recent study, we showed that TNP-nucleotides (Hiratsuka,
2003) are also potent mAC inhibitors; i.e., TNP-ATP and
TNP-GTP inhibit VCI:IIC2 in complex with Gs and FS with
Ki values in the 10 nM range (Mou et al., 2006). Crystallo-
graphic studies showed that the TNP-group binds to the
same hydrophobic pocket as the MANT-group. Like MANT-
nucleotides, TNP-nucleotides are fluorescent and sensitive to
changes in hydrophobicity (Hiratsuka, 2003). Using the bac-
terial AC toxin from Bordetella pertussis, CyaA, as model
system, we showed that MANT-nucleotides and TNP-nucle-
otides complement each other in the exploration of activa-
tion-dependent conformational changes in ACs (Göttle et al.,
2007).
Therefore, the aims of the present study were to examine
the interactions of VC1:IIC2 with TNP-nucleotides using flu-
orescence spectroscopy and to characterize the interactions of
various ACs and sGC with TNP-nucleotides. Moreover, we
examined the interaction of TNP-nucleotides with G-proteins
obtain some information on selectivity of TNP-nucleotides for
other relevant nucleotide-binding proteins involved in signal
transduction. Previous studies from our laboratory showed
that MANT-nucleotides bind to G-proteins with considerably
lower affinity than to ACs (Gille and Seifert, 2003a,b).
Materials and Methods
Materials. VC1, IIC2, and VIIC were purified as described pre-
viously (Tesmer et al., 2002). The expression construct for glutathi-
one S-transferase (GST)-human sAC was generated by cloning the
coding region of human sAC (amino acid residues 1–470) into a
pGEX-KG vector, in which a TEV protease recognition site was
introduced before the start of the human sAC sequence. The plasmid
was transformed into the expression strain Escherichia coli BL-
21(DE3)-pLys and grown in Luria-Bertani medium containing am-
picillin (50 g/ml) until OD  0.5. Thereafter, protein expression was
induced with 30 M isopropyl -D-thiogalactopyranoside at 25°C for
an additional 15 to 18 h. The harvested cells were suspended and
sonicated in lysis buffer (50 mM Tris/HCl, pH 8.0, 50 mM NaCl, 5
mM dithiothreitol, and protease inhibitors). The crude cell lysate
was centrifuged at 18,000g for 1 h at 4°C, and the supernatant fluid
was loaded onto a 5-ml glutathione-Sepharose 4B resin column (GE
Healthcare, Waukesha, WI). The GST-sAC protein was eluted from
the resin with the aforementioned buffer containing 10 mM reduced
glutathione (Sigma-Aldrich, St. Louis, MO). The pooled eluted frac-
tions were digested overnight with TEV protease at 4°C. The TEV-
digested protein was passed through a column with 1 ml of glutathi-
one-Sepharose 4B resin and 0.5 ml of Talon resin (Clontech,
Mountain View, CA) to remove the undigested protein, the GST tag,
and TEV protease. Human sAC was dialyzed against a buffer con-
sisting of 50 mM Tris/HCl, pH 7.5, 30 mM NaCl, 5 mM 2-mercapto-
ethanol, and protease inhibitors. The dialysate was applied onto a
30-ml Fast-Flow Q-Sepharose (GE Healthcare) and eluted with a 0 to
1 M NaCl gradient using an ÄKTA FPLC system (GE Healthcare).
Purified human sAC protein was further passed through sizing col-
umns to remove any remaining contaminants. The purity of the
human sAC protein was 95% as determined by SDS polyacryl-
amide electrophoresis on a 4 to 20% (mass/vol) Tris-HCl polyacryl-
amide gel (Bio-Rad, Hercules, CA) and subsequent Coomassie Blue
staining.
Baculoviruses encoding ACs I, II, and V were donated by Drs.
A. G. Gilman and R. K. Sunahara (University of Texas Southwestern
Medical Center, Dallas, TX). Purified sGC was from Alexis (Lausen,
Switzerland). Construction and expression of 2AR-Gs and FPR-Gi
fusion proteins were described previously (Seifert et al., 1998; Wen-
zel-Seifert et al., 1999; Liu et al., 2001). Sf9 cells were obtained from
the American Type Cell Culture Collection (Manassas, VA). TNP-
ATP, TNP-ADP, and TNP-AMP were purchased from Invitrogen
(Karlsruhe, Germany). TNP-GTP, TNP-GDP, TNP-UTP, and TNP-
CTP were obtained from Jena Bioscience (Jena, Germany). DMB-FS
was obtained from Calbiochem (La Jolla, CA). FS, 2,5-dideoxy-3-
ATP, myokinase, mono(cyclohexyl)ammonium phosphoenol pyru-
vate, and pyruvate kinase were obtained from Sigma-Aldrich.
[-32P]ATP (3000 Ci/mmol), [-32P]GTP (3000 Ci/mmol), and
[-32P]GTP (6000 Ci/mmol) were purchased from PerkinElmer Life
and Analytical Sciences (Boston, MA). Sources of cell culture re-
agents and other materials have been described previously (Wenzel-
Seifert et al., 1999; Gille and Seifert, 2003a; Gille et al., 2004; Mou et
al., 2006).
Cell Culture and Membrane Preparation. Cell culture, ex-
pression, and membrane preparation were carried out as described
previously (Wenzel-Seifert et al., 1999; Gille et al., 2004). In brief,
Sf9 cells were cultured in SF 900 II medium (Invitrogen) with 5%
(v/v) fetal bovine serum and 0.1 mg/ml gentamycin. Sf9 cells were
infected with 1:100 dilutions of baculoviruses encoding different ACs
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or GPCR-G fusion proteins and cultured for 48 h. Cells were then
harvested by centrifugation for 10 min (1000g at 4°C). Pellets were
resuspended in lysis buffer (10 mM Tris/HCl, 1 mM EDTA, 0.2 mM
phenylmethylsulfonyl fluoride, 10 g/ml leupeptin, and 10 g/ml
benzamide, pH 7.4) and disrupted with 20 strokes using a Dounce
homogenizer. The resultant suspension was centrifuged for 5 min
(500g at 4°C) for sedimentation of nuclei. The supernatant fluid
containing the cell membranes was transferred to 30-ml tubes and
centrifuged for 20 min (30,000g at 4°C). The resultant pellet was
then collected and resuspended in storage buffer containing 75 mM
Tris/HCl, 12.5 mM MgCl2, and 1 mM EDTA, pH 7.4. Protein concen-
tration for each membrane was measured using a Bio-Rad DC pro-
tein assay kit. Membrane aliquots (0.5–1 ml each) were stored at
80°C.
AC and GC Activity Assay. The AC activity assay with VC1:
IIC2 was performed as described previously (Mou et al., 2005, 2006).
Assay tubes contained 7 nM VCI and 35 nM IIC2. TNP-nucleotides
(final concentration, 1 nM-100 M) were added. After a preincuba-
tion for 2 min at 30°C, 20 l of reaction mixture containing (final) 100
M cAMP, 40 M ATP, 10 mM MnCl2, 100 mM KCl, 25 mM HEPES/
NaOH, pH 7.4, and 1.0–1.5 Ci/tube [-32P]ATP were added to assay
tubes. After incubation for 1 h at 30°C, reactions were terminated by
adding 20 l of 2.2 N HCl. Denatured protein was sedimented by a
1-min centrifugation at 25°C and 15,000g followed by application of
65 l of the supernatant fluid onto disposable alumina columns
containing 1.3-g neutral alumina (Sigma A-1522, super I, WN-6;
Sigma-Aldrich). To separate [32P]cAMP from [32P]ATP, 4 ml of 0.1 M
ammonium acetate was added for elution of [32P]cAMP. Recovery of
[32P]cAMP was approximately 80% as assessed with [3H]cAMP set as
standard. [32P]cAMP was determined by liquid scintillation counting
using Ecolume scintillation cocktail. AC assays with membranes
from Sf9 cells expressing ACs I, II, and V were conducted as de-
scribed previously (Gille et al., 2004). Membranes were first centri-
fuged for 15 min (15,000g at 4°C), and the pellets were resuspended
in storage buffer. Each assay tube contained membranes expressing
an AC isoform (15–20 g of protein/tube), 10 M GTPS, 40 M ATP,
100 M FS, 1 mM MnCl2 and 100 M cAMP. Reactions were con-
ducted for 20 min at 30°C. Reaction mixtures for sAC contained 200
ng of purified sAC, 50 mM Tris/HCl, pH 7.4, 5 mM MnCl2, 10 mM
CaCl2, 40 M ATP, 1.0–1.5 Ci/tube [-
32P]ATP, and 100 M cAMP.
In some experiments, we assessed the effect of an NTP-regenerating
system consisting of 2.7 mM mono(cyclohexyl)ammonium phospho-
enol pyruvate, 0.125 IU pyruvate kinase, and 1 IU myokinase on the
inhibitory potency of TNP-AMP and TNP-ADP.
sGC activity was determined as described previously (Gille et al.,
2004). In brief, reaction mixtures contained 0.2% (mass/vol) bovine
serum albumin, 5 ng of purified sGC, 30 mM Tris/HCl, pH 7.4, 5 mM
MnCl2, 20 M GTP, 1.0–1.5 Ci [-
32P]GTP, 100 M cGMP, 100 M
sodium nitroprusside, and TNP-nucleotides (final concentration, 1
nM-100 M). [32P]cGMP was separated from [-32P]GTP as de-
scribed for the [32P]cAMP/[-32P]ATP pair.
Fluorescence Spectroscopy. All experiments were carried out
using a Cary Eclipse fluorescence spectrophotometer at 25°C (Varian
Inc., Walnut Creek, CA) as described previously (Mou et al., 2005,
2006; Göttle et al., 2007; Pinto et al., 2009). In brief, measurements
were performed using a quartz fluorescence microcuvette (Hellma,
Plainview, NY) in a final assay volume of 150 l. Steady-state emis-
sion spectra were recorded at low speed with 	ex  405 nm (	em 
500–600 nm). Reaction mixtures contained 100 mM KCl and 10 mM
MnCl2 in 25 mM HEPES/NaOH, pH 7.4, followed by sequential
addition of TNP-nucleotides (final concentration, 5 M), 4 M VCI
plus 25 M IIC2, and 100 M final DMB-FS (water-soluble analog
of FS).
In contrast to MANT-nucleotides, in TNP-nucleotides, the fluores-
cent TNP-group does not isomerize between the 2- and 3-O-ribosyl
position since the TNP substituent is linked to both the 2- and
3-O-ribosyl position simultaneously. Accordingly, TNP-nucleotides
are more rigid molecules than MANT-nucleotides (Hiratsuka, 1983,
2003; Jameson and Eccleston, 1997). Another difference between
MANT-nucleotides and TNP-nucleotides is the fact that the latter
nucleotides exhibit a much lower basal fluorescence than the former
nucleotides, increasing the potential signal-to-noise ratio in fluores-
cence studies (Göttle et al., 2007). Moreover, TNP-nucleotides are
excited in the visible light range (	ex, 405 nm), whereas MANT-
nucleotides are excited in the UV light range (	ex, 350 nm). Thus,
fluorescence studies with TNP-nucleotides are less sensitive to in-
terference with substances absorbing UV light. In MANT-nucleo-
tides, the fluorescent MANT-group can spontaneously isomerize be-
tween the 2- and 3-O-ribosyl position at physiological pH
(Hiratsuka, 1983; Jameson and Eccleston, 1997). Accordingly,
MANT-nucleotides are not clearly defined at any given time.
GTPase Assay. Steady-state GTPase activity was determined as
described previously (Seifert et al., 1998; Wenzel-Seifert et al., 1999;
Liu et al., 2001). In brief, membranes from Sf9 cells expressing
2AR-Gs and FPR-Gi fusion proteins were thawed and centrifuged
for 15 min (15,000g at 4°C) to eliminate any endogenous nucleotides.
Pellets were resuspended in 10 mM Tris/HCl, pH 7.4. Assay tubes
contained 10 g of protein/tube, 1 mM adenylyl imidodiphosphate,
100 nM unlabeled GTP, 100 M ATP, 1 mM MgCl2, 100 M EDTA,
0.2% (mass/vol) bovine serum albumin, 5 mM creatine phosphate,
and 40 g of creatine kinase in 50 mM Tris/HCl, pH 7.4, and increas-
ing concentrations of TNP-ATP or TNP-GTP ranging from 1 M to
1 mM and 10 M isoproterenol (agonist for 2AR-Gs) or 10 M
N-formyl-L-methionyl-L-leucyl-L-phenylalanine (agonist for FPR-Gi)
to fully activate GPCRs and, consequently, GTP hydrolysis by G-
proteins. Assay tubes with the reaction mixtures were incubated for
3 min at 25°C following addition of 20 l of [-32P]GTP (0.2 Ci/
tube). Reactions were carried out for 20 min at 25°C and terminated
by adding 900 l of slurry (5% mass/vol activated charcoal and 50
mM NaH2PO4, pH 2.0). Reaction mixtures were centrifuged for 15
min (15,000g at room temperature). Seven hundred microliters of
supernatant fluid were removed from assay tubes, and 32Pi was
determined by liquid scintillation counting. In the presence of 1 mM
unlabeled GTP, nonenzymatic degradation of [-32P]GTP was deter-
mined and was 
1% of the total amount of radioactivity added.
Molecular Modeling. Docking calculations were carried out us-
ing the GOLD 3.0.1 docking software. As starting point, we used the
crystal structure of VC1:IIC2:FS:Gs-GTPS in complex with TNP-
ATP and two Mn2 ions (Protein Data Bank ID: 1GVD) (Mou et al.,
2006). The bound ligand, TNP-ATP, was used as reference for deter-
mination of the binding of TNP-GTP. All atoms and their associated
residues within 5 Å of each ligand atom were used to define the
catalytic site. The information on ligand hydrogen-bonding interac-
tions and conformations was encoded into the corresponding genetic
algorithm (GA) of GOLD, using the default GOLD 3.0.1 GA param-
eter. The Goldscore and Chemscore scoring functions were used to
rank binding poses. Exogenous TNP-ATP was aligned to the bound
TNP-ATP conformation in the VC1:IIC2 crystal structure. The
docked conformation of the optimally aligned TNP-ATP model mim-
icked the interactions observed in the crystal structure. Thus, the
rigid docking procedure reproduced actual ligand/enzyme interac-
tions. The molecular surface of VC1:IIC2 was calculated with the
PYMOL software.
Data Analysis. All inhibition curves were analyzed by nonlinear
regression using Prism 4.0 software (GraphPad, San Diego, CA).
Fluorescence spectra were analyzed using the spectrum package of
the Cary Eclipse software. For generation of graphs shown in Figs. 1
and 2, data were imported into the Prism software.
Results
Inhibition of the Catalytic Activity of VC1:IIC2 by
TNP-Nucleotides. VC1:IIC2 possesses a broad specificity
for purine and pyrimidine nucleotides as is reflected by the
fact that the fully activated enzyme, i.e., VC1:IIC2 in the
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presence of FS and Gs-GTPS, was inhibited with similar
potency by TNP-ATP, TNP-GTP, and TNP-UTP, followed by
TNP-CTP (Mou et al., 2006). In the presence of FS alone,
TNP-ATP, TNP-UTP, and TNP-CTP were about equally po-
tent VC1:IIC2 inhibitors, followed by TNP-GTP. The omis-
sion of Gs-GTPS had only minor effects on overall TNP-
nucleotide potency (Mou et al., 2006).
For fluorescence studies with TNP-nucleotides, it was
important to determine whether TNP-nucleotides can also
bind to VC1:IIC2 in the absence of activators (Mou et al.,
2005, 2006). In fact, in the absence of the activators FS and
Gs-GTPS, TNP-NDPs and TNP-NTPs inhibited the cata-
lytic activity of VC1:IIC2, with potencies that differed from
each other by 
5-fold (Table 1). However, compared to the
conditions with FS, the potencies of TNP-NTPs were re-
duced by up to 150-fold in the absence of FS (Mou et al.,
2006).
Fluorescence Studies with VC1:IIC2 and TNP-Nucle-
otides. In agreement with previous data (Hiratsuka, 2003;
Göttle et al., 2007), TNP-nucleotides exhibited only small
fluorescence signals in the absence of VC1:IIC2 (Fig. 1). How-
ever, VC1:IIC2 largely increased these fluorescence signals
with TNP-ATP, TNP-ADP, TNP-GTP, TNP-GDP, TNP-CTP,
and TNP-UTP, compatible with the assumption that TNP-
nucleotides bind to the enzyme and that the TNP-group
inserts into the hydrophobic pocket between VC1 and IIC2
that is also occupied by MANT-nucleotides (Mou et al., 2005,
2006). In the absence of VC1:IIC2, TNP-nucleotides exhibited
an emission maximum of 545 nm (Table 2). The addition of
VC1:IIC2 shifted the emission maximum toward shorter
wavelengths, a process referred to as blue-shift. The blue-
shift exhibited nucleotide-specific differences, with TNP-
GDP showing the smallest shift and TNP-UTP showing the
largest shift.
The nonfluorescent ATP analog, 2,5-dideoxy-3-ATP,
binds to the catalytic site of VC1:IIC2 with high affinity
(Tesmer et al., 2000; Gille et al., 2004). To assess the speci-
ficity of the fluorescence increases of TNP-nucleotides upon
addition of VC1:IIC2, we examined the effect of 2,5-dideoxy-
3-ATP. In fact, 2,5-dideoxy-3-ATP (200 M) strongly re-
duced the fluorescence increase of TNP-ATP (5 M) caused
by the addition of VC1:IIC2 (Fig. 2). These data show that
Fig. 1. Fluorescence emission spectra of TNP-nucleotides
in the absence and presence of VC1:IIC2 and DMB-FS.
Fluorescence experiments were performed as described un-
der Materials and Methods. Steady-state emission spectra
of TNP-nucleotides were recorded at 	ex  405 nm and
	em  500 to 600 nm. Cuvettes contained TNP-nucleotides
(5 M each) in the absence or presence of VC1:IIC2 and 100
M DMB-FS. Fluorescence intensities are expressed as
percentage of the maximal emission in the respective ex-
periment and were analyzed using the spectrum package of
the Cary Eclipse software. A, TNP-ATP. B, TNP-ADP. C,
TNP-GTP. D, TNP-GDP. E, TNP-CTP. F, TNP-UTP.
Dashed lines represent emission spectra for TNP-nucleo-
tides alone; solid lines represent spectra in the presence of
TNP-nucleotides plus VC1:IIC2; and dotted lines represent
spectra in the presence of TNP-nucleotides plus VC1:IIC2
plus DMB-FS. Representative fluorescence tracings are
shown. Similar results were obtained in three to four inde-
pendent experiments.



























Fig. 2. Fluorescence emission spectra of TNP-ATP in the absence and
presence of VC1:IIC2 and 2,5-dideoxy-3-ATP. Fluorescence experi-
ments were performed as described under Materials and Methods.
Steady-state emission spectra of TNP-ATP were recorded at 	ex  405 nm
and 	em  500 to 600 nm. Cuvettes contained TNP-ATP (5 M) in the
absence or presence of VC1:IIC2 and 200 M 2,5-dideoxy-3-ATP. Flu-
orescence intensities are expressed as percentage of the maximal emis-
sion and were analyzed using the spectrum package of the Cary Eclipse
software. The dashed line represents the emission spectrum of TNP-ATP
alone; the solid line represents the spectrum in the presence of VC1:IIC2;
and the dotted line represents the spectrum in the presence of VC1:IIC2
plus 2,5-dideoxy-3-ATP. Representative fluorescence tracings are
shown. Similar results were obtained in three independent experiments.
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TNP-nucleotides and 2,5-dideoxy-3-ATP compete for bind-
ing to the catalytic site of VC1:IIC2.
The addition of the water-soluble FS-analog, DMB-FS
(Pinto et al., 2008, 2009), to cuvettes containing TNP-nucle-
otides and VC1:IIC2 decreased the fluorescence signals of
TNP-nucleotides (Fig. 1). However, TNP-nucleotides exhib-
ited large differences in their sensitivity toward reduction of
fluorescence upon addition of DMB-FS. Specifically, with
TNP-ATP, TNP-CTP, and TNP-UTP, large decreases in flu-
orescence were observed, whereas the decrease was moderate
with TNP-ADP and only marginal with TNP-GTP and
TNP-GDP.
Molecular Modeling of the Interaction of TNP-GTP
and TNP-ATP with VC1:IIC2. To obtain direct evidence for
distinct interactions of TNP-nucleotides with VC1:IIC2, we
undertook substantial efforts to produce a crystal structure
of VC1:IIC2 in complex with Gs-GTPS, Mn
2 and TNP-GTP.
Unfortunately, our efforts have been unsuccessful for un-
known reasons (data not shown). Therefore, as an alternative
approach, we conducted molecular modeling studies. Using
the crystal structure of VC1:IIC2 in complex with TNP-ATP
as template (Mou et al., 2006), TNP-GTP was docked into the
catalytic site of the enzyme (Fig. 3). Overall, TNP-ATP and
TNP-GTP adopt similar positions in the catalytic site, and both
nucleotides interact with the amino acids Asn1025 and
Lys1065 of IIC2 (Fig. 3A) (Mou et al., 2006). Figure 3A also
shows the insertion of the TNP-group into the hydrophobic
pocket between IIC2 and VC1, providing an explanation for
the fluorescence increase of TNP-nucleotides upon binding to
the enzyme (Fig. 1). Although TNP-ATP and TNP-GTP bind
to VC1:IIC2 similarly, there are also subtle differences. In
particular, the N2-atom of guanine forms a hydrogen bond
with Asp1018, resulting in slightly different orientations of
both the triphosphate chain and the TNP-group (Fig. 3B).
Inhibition of the Catalytic Activity of AC Isoforms
and sGC by TNP-Nucleotides. ACV inhibitors may be
valuable drugs for the treatment of cardiovascular diseases,
specifically chronic heart failure (Iwatsubo et al., 2004;
Rottlaender et al., 2007; Yan et al., 2007; Göttle et al., 2009),
and sAC inhibitors may represent a novel class of male con-
traceptives (Schlicker et al., 2008). Therefore, we systemati-
cally studied the potencies of TNP-nucleotides for inhibition
of ACs I, II, and V and sAC (Table 3). We also included sGC
into our studies because this enzyme is structurally related
to membranous ACs (Sunahara et al., 1998) and exhibits
broad-base specificity as well (Gille et al., 2004). Moreover,
sGC plays an important role in the regulation of numerous
cardiovascular and neuronal processes, but there is a paucity
of potent and selective substrate-binding site-based sGC inhib-
itors (Derbyshire and Marletta, 2009; Schmidt et al., 2009).
TNP-nucleotides inhibited ACI in the order of potency
TNP-UTP  TNP-ATP  TNP-GTP  TNP-CTP  TNP-
ADP  TNP-GDP   TNP-AMP (Table 3). ACII was less
sensitive to inhibition by TNP-nucleotides than ACI. These
data are in agreement with the results obtained with MANT-
nucleotides (Gille et al., 2004; Göttle et al., 2009). However,
we also noted that the order of potency of TNP-nucleotides for
inhibition of ACs I and II was different. Specifically, the
order of potency for ACII was TNP-UTP  TNP-ATP 
TNP-CTP  TNP-GTP  TNP-ADP  TNP-GDP  TNP-
AMP (Table 3). Like ACI, ACV showed high sensitivity to
inhibition by TNP-nucleotides. These data are again in
agreement with the results obtained with MANT-nucleotides
(Gille et al., 2004; Göttle et al., 2009). However, the inhibitor
profiles were different for both AC isoforms. Specifically,
TNP-nucleotides inhibited ACV in the order of potency: TNP-
ATP  TNP-UTP  TNP-GTP  TNP-CTP  TNP-ADP 
TNP-GDP  TNP-AMP (Table 3). The substantial loss of
potency of TNP-ADP and TNP-AMP relative to TNP-ATP, as
well as TNP-GDP relative to TNP-GTP, in all mACs studied
is explained by the loss of ionic interactions between the -
and -phosphates with Lys1065 of IIC2 and metal ion B (Mou
et al., 2006).
In accordance with the data obtained for MANT-nucleo-
tides (Gille et al., 2004), sAC was considerably less sensitive
to inhibition by TNP-nucleotides than mACs. Among the
compounds examined, TNP-ATP was the most potent sAC
inhibitor, but the nucleotide was 7- to 200-fold less potent
than at ACs I, II, and V (Table 3). These data show that the
structure/activity relationships for nucleotide-based inhibi-
tors of mACs and sAC are quite different and that it will be
very challenging to obtain highly potent AC inhibitors with
selectivity relative to mACs.
In marked contrast, sGC was very sensitive to inhibition
by TNP-nucleotides, with ACV and sGC showing substantial
similarities in the inhibition profile (Table 3). TNP-ATP was
a slightly more potent sGC inhibitor than TNP-GTP. Nota-
bly, the pyrimidine nucleotides TNP-UTP and TNP-CTP
were just 3- to 5-fold less potent sGC inhibitors than the
TABLE 1
Inhibition of VC1:IIC2 by TNP-nucleotides
AC activity was determined as described under Materials and Methods in the
presence of Mn2. Reaction mixtures contained TNP-nucleotides at concentrations
from 1 nM to 100 M as appropriate to generate saturated inhibition curves.
Inhibition curves were analyzed by nonlinear regression and were best-fitted to
monophasic sigmoidal curves. Ki values were calculated from IC50 values using the
previously determined Km values (Mou et al., 2005). Data shown are the means 




TNP-ADP 11,000  5900
TNP-ATP 3300  1400
TNP-GDP 15,000  1000
TNP-GTP 6400  2000
TNP-UTP 14,000  1200
TNP-CTP 8600  1100
TABLE 2
Emission peaks of TNP-nucleotides in the absence and presence of
VC1:IIC2
Fluorescence experiments were performed as described under Materials and Meth-
ods. Steady-state emission spectra of TNP-nucleotides in the presence of Mn2 were
recorded at 	ex  405 nm and 	em  500 to 600 nm in the absence or presence of
VC1:IIC2. The concentration of TNP-nucleotides was 5 M each. The blue-shift is the
difference between the emission maximum in the absence and presence of VC1:IIC2.
Fluorescence recordings were calculated with the spectrum package of the Cary












TNP-ADP 545  1 532  1 13  1
TNP-ATP 545  2 532  2 14  2
TNP-GDP 545  1 540  1 5  1
TNP-GTP 545  1 537  1 8  1
TNP-UTP 545  3 528  3 17  3
TNP-CTP 545  1 532  1 13  1
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purine nucleotides. To the best of our knowledge, TNP-ATP is
the most potent sGC inhibitor reported so far (Derbyshire
and Marletta, 2009; Schmidt et al., 2009). Cell membrane-
permeable TNP-nucleotides may become very valuable tools
for the analysis of sGC in cardiovascular and neuronal func-
tions. Moreover, TNP-nucleotides may be useful ligands
for crystallizing sGC, of which the goal has not yet been
accomplished.
Inhibition of the Catalytic Activity of Gs- and Gi-
Proteins by TNP-Nucleotides. The steady-state GTPase
assay with GPCR-G fusion proteins is a very well suited
assay for the determination of Gi- and Gs-protein affinities
for nucleotides (Seifert et al., 1999; Gille et al., 2002, 2005;
Gille and Seifert, 2003b). In a previous study we showed
that MANT-guanosine 5-[-thio]triphosphate and MANT-
guanosine 5-[,-imido]triphosphate bind to Gi- and Gs-pro-
teins with low-affinity, i.e., in the 0.2 to 1.0 M and 1 to 6 M
range, respectively (Gille and Seifert, 2003b). This low-affin-
ity interaction of MANT-nucleotides is explained by the tight
guanine nucleotide-binding pocket of G-protein -subunits,
leaving little space to accommodate bulky substituents at the
2- and 3-O-ribosyl position (Seifert and Gille, 2003b). Ac-
cordingly, we expected the conformationally constrained
TNP-nucleotides also to bind to G-proteins with low affinity.
Indeed, TNP-GTP inhibited the agonist-stimulated steady-
state GTP hydrolysis of various 2AR-Gs and FPR-Gi fu-
sion proteins only with Ki values in the 10 to 30 M range
(Table 4). Considering then that TNP-GTP inhibits holo-ACs
and sGC with Ki values in the 10 to 200 nM range (Table 3),
it becomes clear that TNP-GTP exhibits an exquisite selec-
tivity for nucleotidyl cyclases compared with G-proteins.
TNP-ATP binds to Gs- and Gi-proteins with even lower affin-
ity than TNP-GTP, i.e., with Ki values 50 to 100 M. Thus,
TNP-ATP exhibits 1000-fold selectivity for some ACs rela-
tive to G-proteins. The low affinity of G-proteins for TNP-
GTP also implies that this nucleotide is very unlikely to be
useful as fluorescent probe for monitoring conformational
changes in G-proteins.
Discussion
TNP-Nucleotides as Experimental Tools. TNP-nucleo-
tides are broadly used as fluorescence probes for many nu-
cleotide-binding proteins, including receptors, enzymes, and
structural proteins (Hiratsuka, 2003). To the best of our
knowledge, mACs exhibit the highest affinity for TNP-nucle-
otides among all target proteins studied so far (Table 3). Most
proteins bind TNP-nucleotides with affinities in the micro-
molar range (Hiratsuka, 2003), whereas several ACs and
sGC exhibit affinities for TNP-nucleotides in the nanomolar
range (Tables 1 and 3) (Mou et al., 2006). Moreover, TNP-
nucleotides possess an excellent selectivity for mACs relative
to G-proteins (Table 4). This striking selectivity of TNP-
nucleotides for mACs relative to G-proteins could be ex-
ploited in electrophysiological signal transduction studies
with intact cells in which nucleotides are introduced as AC
inhibitors into the cytosol via the patch pipette (Rottlaender
et al., 2007).
Broad-Base Specificity of ACs and sGC. Our present
study corroborates the unexpected notion that mACs exhibit
a broad-base specificity and high conformational flexibility
(Gille and Seifert, 2003; Gille et al., 2004; Mou et al., 2005,
2006; Göttle et al., 2009). This notion can be extended to
structurally unrelated bacterial AC toxins (Göttle et al.,
2007; Taha et al., 2009) and, as shown here, to sGC and sAC
(Table 3). Thus, despite the substantial structural differences
between all of the nucleotidyl cyclases studied so far (Su-
nahara et al., 1998; Sunahara and Taussig, 2002; Ahuja et
Fig. 3. Model of TNP-ATP and TNP-GTP binding to VC1:IIC2. Docking
studies were performed as described under Materials and Methods. The
crystal structure of VC1:IIC2:FS:Gs-GTPS:TNP-ATP (Protein Data Bank
ID: 1GVD) served as template for docking TNP-GTP into the catalytic
site. Docking calculations were carried out using the GOLD 3.0.1 soft-
ware. A, superimposition of TNP-ATP and TNP-GTP in the catalytic core
of VC1:IIC2. Ligands are shown as stick models; carbon atoms are gray
for TNP-ATP and cyan for TNP-GTP. Nitrogen, oxygen, and phosphorus
atoms are shown in blue, red, and green, respectively. Mn2 is shown as
orange sphere. The AC surface is shown as a solvent-accessible molecular
surface: red representing acidic surfaces, blue representing basic sur-
faces, and gray representing hydrophobic surfaces. B, detailed view of the
superimposition of TNP-ATP and TNP-GTP in the catalytic core of VC1:
IIC2, with the molecular surface removed. In the bottom left corner, the
hydrogen bonds between N2 of the guanine ring and Asp1018 are shown.
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al., 2004), broad-base specificity is a common and highly
conserved theme in this enzyme class. The broad-base spec-
ificity and conformational flexibility, however, do not imply
that all nucleotidyl cyclases exhibit identical pharmacologi-
cal profiles. In fact, each nucleotidyl cyclase exhibits a unique
profile (Table 3). Moreover, the differential effects of
DMB-FS and the differences in blue-shift in our fluorescence
studies revealed that purine and pyrimidine nucleotides bind
to the catalytic site of at least one AC (VCI:IIC2) in slightly
different manners (Fig. 1; Table 2).
We also would have liked to have conducted fluorescence
studies with sGC that based on the high affinity of this
enzyme for TNP-nucleotides are technically feasible. How-
ever, a drawback of the fluorescence studies is the fact that
high protein concentrations (in the 5–25 M range) are re-
quired (see Materials and Methods). Unfortunately, it is not
yet possible to obtain such large amounts of sGC. Conversely,
large amounts of recombinant sAC can be readily obtained
(see Materials and Methods), but the affinity of sAC for
TNP-nucleotides is too low for fluorescence studies (Table 3).
Whereas MANT-nucleotides are more potent inhibitors of
VC1:IIC2 than of holo-ACs I and V (Gille et al., 2004), the
opposite is true of TNP-nucleotides (Tables 1 and 3) (Mou et
al., 2006). Thus, the structural constraints in TNP-nucleo-
tides caused by the dual and nonisomerizing 2- and 3-O-
ribosyl modification compared with the isomerizing 2- and
3-O-ribosyl isomerization in MANT-nucleotides (Jameson
and Eccleston, 1997; Hiratsuka, 2003) facilitate binding to
holo-ACs. A major structural difference between VC1:IIC2
and holo-ACs is that the former enzyme is completely devoid
of the transmembrane domains (Sunahara and Taussig,
2002). These data indicate that the transmembrane domains,
perhaps by modulation of the mobility of the catalytic do-
mains, differentially regulate inhibitor affinities of holo-ACs.
The high affinity of ACs I, II, and V and sGC for TNP-UTP
and TNP-CTP is quite remarkable. These data raise the
intriguing question whether UTP and CTP can also be sub-
strates for ACs. In support of such a possibility is the fact
that both 3,5-cyclic CMP and 3,5-cyclic UMP do, indeed,
occur in mammalian tissues as shown by sensitive mass
spectrometry techniques (Newton et al., 1984, 1986). More-
over, in experiments with [-32P]UTP as substrate,
[32P]cUMP was identified as a bona fide product of sGC (Gille
et al., 2004), but direct structural confirmation of cUMP
production by sGC with mass spectrometry techniques is still
missing. The structural identity of the putative mammalian
cytidylyl cyclase is elusive as well (Newton et al., 1990).
Comparison of TNP-Nucleotides and MANT-Nucleo-
tides as Fluorescence Probes. The crystal structures of
VC1:IIC2 with MANT-GTP, MANT-ATP, and TNP-ATP
show that, in all three cases, the fluorescent group, be it a
MANT-group or a TNP-group, resides in a hydrophobic
pocket between the VC1 and IIC2 subunit (Mou et al., 2005,
2006). Because both MANT-nucleotides and TNP-nucleotides
respond with an increase in fluorescence upon exposure to a
hydrophobic environment (Jameson and Eccleston, 1997;
Hiratsuka, 2003), one may have predicted to observe similar
fluorescence changes with both classes of nucleotides upon
interaction with VC1:IIC2. However, this was clearly not the
case. Most strikingly, even in the absence of DMB-FS, VC1:
IIC2 caused large fluorescence increases with TNP-nucleo-
tides and blue-shifts of the emission maximum (Fig. 1; Table
2), indicating that the hydrophobic pocket between both sub-
units can already form in the absence of AC activators. In
contrast, MANT-nucleotides are quite ineffective at inserting
into the hydrophobic pocket of VCI:IIC2 in the absence of
activators (Mou et al., 2005, 2006). Whereas FS translocates
the MANT-group into a more hydrophobic environment, re-
sulting in fluorescence increases (Mou et al., 2005, 2006;
Pinto et al., 2009), FS translocates the TNP-group into a
more hydrophilic environment, resulting in fluorescence de-
creases. Intriguingly, both among MANT-nucleotides (Mou et
al., 2006) and TNP-nucleotides (Fig. 1; Table 2), there are
substantial base-specific differences in fluorescence proper-
ties. Those differences were not predicted either by crystal-
lographic studies (Mou et al., 2006) or molecular modeling
studies (Fig. 3). Thus, fluorescence spectroscopy is much
more sensitive than crystallography and molecular modeling
TABLE 3
Inhibition of various AC isoforms and sGC by TNP-nucleotides
mAC, sAC, and sGC activity was determined as described under Materials and Methods in the presence of Mn2. Reaction mixtures contained TNP-nucleotides at
concentrations from 1 nM to 100 M as appropriate to generate saturated inhibition curves. Inhibition curves were analyzed by nonlinear regression and were best-fitted
to monophasic sigmoidal curves. Ki values were calculated from IC50 values using the previously determined Km values (Gille et al., 2004). Km for sAC was 380  20 M,
and Vmax was 760 nmol/mg/min. Data shown are the means  S.D. of three to six experiments performed in duplicates.
TNP-Nucleotide Ki ACI Ki ACII Ki ACV Ki sAC Ki sGC
nM
TNP-AMP 4800  1000 7400  520 4800  1200 N.D. N.D.
TNP-ADP 140  17 1100  180 370  45 N.D. N.D.
TNP-ATP 9.0  4.1 99  2.7 3.7  1.0 710  82 7.3  1.7
TNP-GDP 410  76 3400  1300 1200  280 N.D. N.D.
TNP-GTP 23  2.2 220  30 27  4.3 7200  280 8.6  2.6
TNP-UTP 7.1  2.3 24  8.4 15  2.2 3100  50 33  6.9
TNP-CTP 24  2.9 110  35 31  3.9 5100  480 27  0.9
N.D., not determined.
TABLE 4
Affinities of Gs- and Gi-proteins for TNP-ATP and TNP-GTP
High-affinity GTPase activity in Sf9 membranes expressing various GPCR-G fusion
proteins was determined as described under Materials and Methods in the presence
of Mg2. Reaction mixtures contained TNP-nucleotides at concentrations from 1 nM
to 100 M as appropriate to generate saturated inhibition curves. Inhibition curves
were analyzed by nonlinear regression and were best-fitted to monophasic sigmoidal
curves. Ki values were calculated from IC50 values using the previously determined
Km values (Gille and Seifert, 2003b). Data shown are the means  S.D. of three
experiments performed in duplicates.
Construct Ki TNP-ATP Ki TNP-GTP
nM
2AR-GsS 53,000  11,000 12,000  1500
2AR-GsL 100,000 17,000  2100
2AR-Golf 100,000 26,000  3400
FPR-Gi1 100,000 12,000  3100
FPR-Gi2 100,000 6900  1300
FPR-Gi3 100,000 10,000  2200
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at revealing very subtle conformational differences among
similar ligands bound to mAC. These data corroborate the
concept of conformational flexibility of ACs.
There are also some interesting similarities in the fluores-
cence properties of MANT-nucleotides and TNP-nucleotides
at VC1:IIC2 compared with the bacterial AC toxin CyaA that
is activated by calmodulin. Specifically, with MANT-nucleo-
tides, there is an increase in direct fluorescence and fluores-
cence resonance energy transfer upon interaction of CyaA
with calmodulin, whereas with TNP-nucleotides, there is a
calmodulin-dependent decrease in fluorescence (Göttle et al.,
2007). The mAC activator FS revealed similar patterns with
MANT- and TNP-nucleotides at VCI:IIC2 (Mou et al., 2005,
2006; Pinto et al., 2009) (Fig. 2). Moreover, the fluorescence
decreases with TNP-nucleotides at CyaA are, like with VC1:
IIC2, base-dependent. Strikingly, the activation-dependent
decreases in fluorescence at CyaA and VC1:IIC2 with TNP-
nucleotides were most prominent for the pyrimidine bases
(Göttle et al., 2007). These data indicate that, despite the
substantial structural differences between mammalian
membranous ACs and the bacterial AC toxin (Sunahara and
Taussig, 2002; Ahuja et al., 2004), there are common and
highly conserved themes in activation-dependent conforma-
tional changes in both classes of enzymes. Probably, these
conserved conformational changes are directly related to the
broad-base specificity found in mACs and bacterial AC toxins
(Gille et al., 2004, 2005; Mou et al., 2006; Göttle et al., 2007,
2009; Taha et al., 2009). Like mAC and CyaA, edema factor
AC toxin from Bacillus anthracis shows activation-depen-
dent fluorescence increases with MANT-nucleotides (Taha et
al., 2009). However, the affinity of edema factor for TNP-
nucleotides is too low to allow for the conduction of fluores-
cence studies (data not shown).
Future Development of mAC Inhibitors. The develop-
ment of isoform-selective AC inhibitors is an important and
ambitious long-term goal. In particular, ACV inhibitors are
promising drug candidates for the treatment of heart failure
and ageing-related diseases (Iwatsubo et al., 2004; Rottla-
ender et al., 2007; Yan et al., 2007; Göttle et al., 2009). The
identification of TNP-nucleotides as holo-AC inhibitors is an
important step toward the achievement of this goal since
TNP-nucleotides surpass the corresponding MANT-nucleo-
tides in terms of potency at ACV by up to 50-fold (Table 3)
(Gille et al., 2004; Göttle et al., 2009). MANT-inosine 5-
triphosphate is the most potent ACV inhibitor known so far
(Ki, 1 nM) (Göttle et al., 2009). Thus, we predict that TNP-
inosine 5-triphosphate, which is not available to us at the
present time, will be an even more potent ACV inhibitor.
Whereas TNP-nucleotides do not surpass MANT-nucleotides
in terms of AC isoform selectivity, the 2,3-O-ribosyl substi-
tution with a phenyl ring offers numerous opportunities for
chemical modifications. Specifically, some of the nitro groups
attached to the phenyl ring could be deleted or exchanged
against other functional groups. Given the conformational
flexibility of the catalytic site of mACs together with the fact
that the inhibition profiles of various mACs are not identical,
the systematic analysis of the structure/activity relation-
ships of phenyl ring substitutions combined with molecular
modeling studies may ultimately yield AC isoform-selective
inhibitors.
In a previous study, we showed that MANT-GDP and
MANT-ADP are phosphorylated to MANT-GTP and MANT-
ATP, respectively, by the NTP-regenerating system consist-
ing of mono(cyclohexyl)ammonium phosphoenol pyruvate,
pyruvate kinase, and myokinase (Gille et al., 2004). Like-
wise, the NTP-regenerating system increased the inhibitory
potencies of TNP-AMP and TNP-ADP to the values of TNP-
ATP using ACV as model AC (data not shown). These data
show that TNP-AMP and TNP-ADP can be readily phosphor-
ylated. This is an important property for intact cell experi-
ments with lipophilic pronucleotide inhibitors that have to be
converted to the actual inhibitory compounds (Laux et al.,
2004). Thus, the present study provides an important start-
ing point for the development of potent and selective mAC
and sGC inhibitors.
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